KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Account Payables: 2018-2024

Historic Change in Account Payables for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to -$4.4 million.

  • Castle Biosciences' Change in Account Payables rose 165.33% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 420.43%. This contributed to the annual value of -$4.4 million for FY2024, which is 176.61% down from last year.
  • Per Castle Biosciences' latest filing, its Change in Account Payables stood at -$4.4 million for FY2024, which was down 176.61% from $5.7 million recorded in FY2023.
  • Castle Biosciences' 5-year Change in Account Payables high stood at $5.7 million for FY2023, and its period low was -$4.4 million during FY2024.
  • In the last 3 years, Castle Biosciences' Change in Account Payables had a median value of $582,000 in 2022 and averaged $639,000.
  • In the last 5 years, Castle Biosciences' Change in Account Payables slumped by 207.69% in 2021 and then skyrocketed by 880.58% in 2023.
  • Yearly analysis of 5 years shows Castle Biosciences' Change in Account Payables stood at $169,000 in 2020, then crashed by 207.69% to -$182,000 in 2021, then skyrocketed by 419.78% to $582,000 in 2022, then surged by 880.58% to $5.7 million in 2023, then slumped by 176.61% to -$4.4 million in 2024.